Alterity Therapeutics (ATHE) Shares Outstanding (Weighted Average) (2009 - 2025)

Alterity Therapeutics' Shares Outstanding (Weighted Average) history runs 14 years deep, the most recent figure standing at $185491.4 billion for Q4 2025.

• In Q4 2025, Shares Outstanding (Weighted Average) rose 26.9% year-over-year to $185491.4 billion; the TTM figure through Dec 2025 stood at $185491.4 billion (up 26.9% YoY), while the FY2025 annual figure was $168401.6 billion, up 4871700.94% from the prior year.
• Shares Outstanding (Weighted Average) was $185491.4 billion for Q4 2025 at Alterity Therapeutics, up from $168401.6 billion in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $185491.4 billion in Q4 2025 to a low of $143.0 million in Q2 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $93627.1 billion across 5 years, with a median of $140218.3 billion in 2022.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) slumped 90.46% in 2022, then jumped 4871700.94% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $155764.2 billion in 2021, then dropped by 9.81% to $140489.0 billion in 2022, then dropped by 0.39% to $139947.6 billion in 2023, then advanced by 4.45% to $146172.1 billion in 2024, then gained by 26.9% to $185491.4 billion in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $185491.4 billion (Q4 2025), $168401.6 billion (Q2 2025), and $146172.1 billion (Q4 2024), per Business Quant data.